|
1
|
Greenlee RT, Hill-Harmon MB, Murray T and
Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li L, Sun X, Wang X and Ding C: WITHDRAWN:
MicroRNA-200c and microRNA-141 as potential diagnostic and
prognostic biomarkers for ovarian cancer. Biomed Pharmacother: pii:
S0753-S3322. 00213-3. 2014. View Article : Google Scholar
|
|
5
|
Banno K, Yanokura M, Iida M, Adachi M,
Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Nomura H, et al:
Application of microRNA in diagnosis and treatment of ovarian
cancer. Biomed Res Int. 2014:2328172014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu L, Zou J, Wang Q, Yin FQ, Zhang W and
Li L: Novel microRNAs expression of patients with chemotherapy
drug-resistant and chemotherapy-sensitive epithelial ovarian
cancer. Tumour Biol. 35:7713–7717. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Clop A, Marcq F, Takeda H, Pirottin D,
Tordoir X, Bibé B, Bouix J, Caiment F, Elsen JM, Eychenne F, et al:
A mutation creating a potential illegitimate microRNA target site
in the myostatin gene affects muscularity in sheep. Nat Genet.
38:813–818. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh SR and Rameshwar P: MicroRNA in
Development and in the Progression of Cancer (1st). Springer. New
York City, NY: 2014. View Article : Google Scholar
|
|
10
|
Kinose Y, Sawada K, Nakamura K and Kimura
T: The role of microRNAs in ovarian cancer. Biomed Res Int.
2014:2493932014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kan CW, Howell VM, Hahn MA and Marsh DJ:
Genomic alterations as mediators of miRNA dysregulation in ovarian
cancer. Genes Chromosomes Cancer. 54:1–19. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Yao L, Liu F, Hong J, Chen L, Zhang
B and Zhang W: Characterization of microRNA expression in serous
ovarian carcinoma. Int J Mol Med. 34:491–498. 2014.PubMed/NCBI
|
|
13
|
Liu N, Zhou C, Zhao J and Chen Y: Reversal
of paclitaxel resistance in epithelial ovarian carcinoma cells by a
MUC1 aptamer-let-7i chimera. Cancer Invest. 30:577–582. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee IH, Park JB, Cheong M, Choi YS, Park D
and Sin JI: Antitumor therapeutic and antimetastatic activity of
electroporation-delivered human papillomavirus 16 E7 DNA vaccines:
A possible mechanism for enhanced tumor control. DNA Cell Biol.
30:975–985. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nurkkala M, Wassén L, Nordström I,
Gustavsson I, Slavica L, Josefsson A and Eriksson K: Conjugation of
HPV16 E7 to cholera toxin enhances the HPV-specific T-cell recall
responses to pulsed dendritic cells in vitro in women with cervical
dysplasia. Vaccine. 28:5828–5836. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly
KA, Calin GA, Li Z, Bast RC Jr and Le XF: Clinically relevant
microRNAs in ovarian cancer. Mol Cancer Res. 13:393–401. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L
and Wang Z: MiR-27a modulates MDR1/P-glycoprotein expression by
targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol.
119:125–130. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luo J, Zhou J, Cheng Q, Zhou C and Ding Z:
Role of microRNA-133a in epithelial ovarian cancer pathogenesis and
progression. Oncol Lett. 7:1043–1048. 2014.PubMed/NCBI
|
|
19
|
Zong C, Wang J and Shi TM: MicroRNA 130b
enhances drug resistance in human ovarian cancer cells. Tumour
Biol. 35:12151–12156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li B, Chen H, Wu N, Zhang WJ and Shang LX:
Deregulation of miR-128 in ovarian cancer promotes cisplatin
resistance. Int J Gynecol Cancer. 24:1381–1388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim
JH, Kim JW and Kim S: MicroRNA expression profiles in serous
ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang XY, Ding JX, Tao X and Hua KQ: FSH
stimulates expression of the embryonic gene HMGA2 by downregulating
let-7 in normal fimbrial epithelial cells of ovarian high-grade
serous carcinomas. Exp Ther Med. 5:350–354. 2013.PubMed/NCBI
|
|
23
|
Wan WN, Zhang YQ, Wang XM, Liu YJ, Zhang
YX, Que YH, Zhao WJ and Li P: Down-regulated miR-22 as predictive
biomarkers for prognosis of epithelial ovarian cancer. Diagn
Pathol. 9:1782014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen S, Chen X, Xiu YL, Sun KX, Zong ZH
and Zhao Y: MicroRNA 490-3P enhances the drug-resistance of human
ovarian cancer cells. J Ovarian Res. 7:842014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu CL and Gao GS: miR-200a overexpression
in advanced ovarian carcinomas as a prognostic indicator. Asian Pac
J Cancer Prev. 15:8595–8601. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao H, Liu S, Wang G, Wu X, Ding Y, Guo
G, Jiang J and Cui S: Expression of miR-136 is associated with the
primary cisplatin resistance of human epithelial ovarian cancer.
Oncol Rep. 33:591–598. 2015.PubMed/NCBI
|
|
27
|
Li L, He L, Zhao JL, Xiao J, Liu M, Li X
and Tang H: miR-17-5p up-regulates YES1 to modulate the cell cycle
progression and apoptosis in ovarian cancer cell lines. J Cell
Biochem. 116:1050–1059. 2015. View Article : Google Scholar : PubMed/NCBI
|
